PF-05280014

10/01/2018 - "The efficacy of PF-05280014 was equivalent to that of reference trastuzumab in women with HER2-positive metastatic breast cancer and was comparable to that of reference trastuzumab in those with HER2-positive early breast cancer. "
10/01/2018 - "PF-05280014 has similar physicochemical and pharmacodynamic properties to those of reference trastuzumab, and the pharmacokinetic similarity of the agents has been shown in women with metastatic or early HER2-positive breast cancer and healthy male volunteers. "
01/01/2018 - "PF-05280014 demonstrated non-inferior pharmacokinetics and comparable efficacy, safety and immunogenicity to trastuzumab-EU in patients with operable HER2-positive breast cancer receiving neoadjuvant chemotherapy."
01/01/2019 - "When given as first-line treatment for HER2-positive metastatic breast cancer, PF-05280014 plus paclitaxel demonstrated equivalence to trastuzumab-EU plus paclitaxel in terms of ORR. "
12/01/2022 - "The PF-05280014 might be a better trastuzumab biosimilar in the treatment of HER2-positive breast cancer patients."

01/01/2019 - "Treatment with PF-05280014 or trastuzumab-EU could continue until disease progression. "
01/01/2022 - "Randomized patients received intravenous PF-05280014 or trastuzumab-EU, each plus paclitaxel, until objective disease progression. "

10/01/2014 - "PF-05280014, trastuzumab-US, and trastuzumab-EU were well tolerated during the 4-month observation period following a single dose of up to 100 mg/kg. PF-05280014, trastuzumab-US, and trastuzumab-EU showed similar structural properties, tumor cell growth inhibition properties, and PK profiles. "
10/01/2014 - "The tumor cell growth inhibition of PF-05280014 was similar to trastuzumab-US and trastuzumab-EU. "
01/01/2019 - "Five trastuzumab biosimilars: MYL-1401O (Ogivri), CT-P6 (Herzuma), SB3 (Ontruzant), PF-05280014 (Trazimera), and ABP980 (Kanjinti), have now been approved by the US Food and Drug Administration (FDA) for use in HER2-positive breast cancers. "

10/01/2018 - "The role of reference trastuzumab in the management of HER2-positive breast and gastric cancers is well established and PF-05280014 provides an effective biosimilar alternative for patients requiring trastuzumab therapy."

12/01/2014 - "The AE term 'pyrexia' was numerically greater in the PF-05280014 arm. "